Marshall Wace, LLP Surface Oncology, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.62 - $1.21 $59,535 - $116,190	-96,025 Reduced 46.4%	110,928 $90,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $97,408 - $194,817	92,770 Added 81.25%	206,953 $216,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $162,139 - $359,676	114,183 New	114,183 $188,000
Q4 2021 Feb 14, 2022	SELL	$4.73 - $7.9 $1.1 Million - $1.83 Million	-232,162 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.16 - $7.98 $1.2 Million - $1.85 Million	232,162 New	232,162 $1.76 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.